The skin and mucous membranes are the primary sites of Kaposi's sarcoma (KS), an uncommon, intricate, and frequently aggressive malignancy that can potentially affect internal organs. Moritz Kaposi, a dermatologist from Hungary, originally described it in the late 19th century, and since then, our understanding of it has advanced tremendously. The human herpesvirus 8 (HHV-8), commonly known as the Kaposi's sarcoma-associated herpesvirus (KSHV), is strongly linked to KS and is essential for the growth of this cancer. Purplish or reddish skin lesions that might vary in size and appearance are the most common KS symptoms. These disfiguring lesions frequently affect the lower limbs, the face, or the genital region. Internal organs like the lungs, liver, and gastrointestinal tract may be affected by KS in some circumstances, which can result in more serious symptoms and problems. Classic KS, which mostly affects elderly men of Mediterranean or Eastern European descent, is one type of KS. Other types include endemic KS, which is common in equatorial Africa, iatrogenic KS, which is linked to immunosuppressive therapy, and epidemic or AIDS-related KS, which gained widespread attention during the HIV/AIDS epidemic of the 1980s and 1990s. Since the immune system plays a key role in the development of KS, people with compromised immune systems, such as those with HIV/AIDS or those receiving immunosuppressive therapy after organ transplantation, are more likely to contract the condition. The weakened immune system enables HHV-8 replication and accelerates the development of KS lesions. The form, severity, and general health of the patient are among the variables that affect how Kaposi's sarcoma is managed. Antiretroviral therapy, local therapies such radiation or topical medicines for skin lesions, chemotherapy for more severe cases, and immunomodulatory medications are also possible forms of treatment. For KS patients to have a better prognosis and quality of life, early detection and treatments are essential. Recent developments in the knowledge of the molecular mechanisms behind Kaposi's sarcoma and the creation of targeted medicines have given rise to fresh optimism for improved results. KS is still a difficult illness, highlighting the significance of continued research and healthcare initiatives to control and ultimately treat this difficult cancer.